[Cytoprotective effect of Amifostine in the combined chemotherapy of advanced ovarian carcinoma].
The authors treated 10 patients with advanced (stage III-IV) ovarian cancer with a high-dose cyclophosphamide and cisplatin (CP) combined therapy in amifostine protection. Due to the effect of the cytoprotective agent the cycles of treatment were well tolerated and 7 of 10 patients achieved a complete remission. Nephrotoxicity, allergic reaction or minor complications did not occur. Starting of the next treatment cycle was to be delayed in only one case because of anaemia. The agent has an implicit place in the treatment of patients with ovarian cancer in order to achieve better results and improve the quality of life.
Nagy
P
P
Zala Megyei Kórház, Zalaegerszeg, Szülészet-nógyógyászati Osztály.
Kádasi
L
L
D000368:Aged; D004999:Amifostine / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D002277:Carcinoma / Q000188:drug therapy* / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000009:adverse effects; D003520:Cyclophosphamide / Q000009:adverse effects; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D011837:Radiation-Protective Agents / Q000627:therapeutic use*; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D016896:Treatment Outcome
D011837:Radiation-Protective Agents; D003520:Cyclophosphamide; D004999:Amifostine; D002945:Cisplatin